Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cholecystokinin tetrapeptide (CCK-4) is a synthetic tetrapeptide fragment corresponding to the four C-terminal amino acids of the endogenous hormone cholecystokinin. It is used in research as a panicogenic probe, as intravenous administration reliably induces panic- and anxiety-like symptoms in humans, particularly in healthy volunteers and individuals with panic disorder. The panic-like symptoms are thought to arise through direct or indirect activation of central cholecystokinin receptors and related neuronal pathways. CCK-4 is not used therapeutically or diagnostically in clinical medicine, but rather as a tool compound for modeling panic attacks in neuropsychiatric research and for evaluation of anxiolytic drugs[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cholecystokinin tetrapeptide.